Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Trial Profile

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Landipirdine (Primary)
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors Biotie Therapies Corp.
  • Most Recent Events

    • 09 Oct 2018 Results assessing impact of Landipirdine on psychiatric symptoms, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
    • 09 Oct 2018 Primary endpoint has not been met. (Change in Cognitive Drug Research Computerized Cognition Battery (CDR) Continuity of Attention from baseline)
    • 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top